Oral IIb/IIIa inhibition and revascularization: Preliminary results from OPUS-TIMI 16 (Orbofiban in patients with unstable coronary syndromes)

被引：0
|
作者：
Cannon, CP
McCabe, CH
Wilcox, RG
Charlesworth, A
Foxley, A
Anders, RJ
Alexander, JC
Skene, AM
Braunwald, E
机构：
[1] Queens Med Ctr, Nottingham NG7 2UH, England
[2] Brigham & Womens Hosp, Boston, MA 02115 USA
[3] Nottingham Clin Trial Data Ctr, Nottingham, England
[4] Searle, Skokie, IL USA
来源：
CIRCULATION | 1999年 / 100卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2626
引用
收藏
页码：498 / 498
页数：1
相关论文
共 50 条
  • [1] Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
    Cannon, CP
    McCabe, CH
    Wilcox, RG
    Langer, A
    Caspi, A
    Berink, P
    Lopez-Sendon, J
    Toman, J
    Charlesworth, A
    Anders, RJ
    Alexander, JC
    Skene, A
    Braunwald, E
    CIRCULATION, 2000, 102 (02) : 149 - 156
  • [2] Drug-induced thrombocytopenia and thrombosis: Evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable Coronary Syndromes-(OPUS-TIMI 16) trial
    Scirica, Benjamin M.
    Cannon, Christopher P.
    Cooper, Richard
    Aster, Richard H.
    Brassard, Jacqueline
    McCabe, Carolyn H.
    Charlesworth, Andrew
    Skene, Allan M.
    Braunwald, Eugene
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2006, 22 (02) : 95 - 102
  • [3] Drug-induced thrombocytopenia and thrombosis: Evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial
    Benjamin M. Scirica
    Christopher P. Cannon
    Richard Cooper
    Richard H. Aster
    Jacqueline Brassard
    Carolyn H. McCabe
    Andrew Charlesworth
    Allan M. Skene
    Eugene Braunwald
    Journal of Thrombosis and Thrombolysis, 2006, 22 : 95 - 102
  • [4] Orbofiban in unstable angina (OPUS-TIMI 16 trial)
    Ellis G.
    Current Controlled Trials in Cardiovascular Medicine, 2000, 2 (1): : 130
  • [5] Thrombocytopenia, bleeding and thrombotic events with oral glycoprotein IIb/IIIa inhibition: Results from OPUS-TIMI 16
    Coulter, SA
    Cannon, CP
    Cooper, RA
    McCabe, CH
    Aster, R
    Charlesworth, A
    Skene, AM
    Braunwald, E
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (02) : 393A - 393A
  • [6] Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study
    Smith, EE
    Cannon, CP
    Murphy, S
    Feske, SK
    Schwamm, LH
    AMERICAN HEART JOURNAL, 2006, 151 (02) : 338 - 344
  • [7] Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: Analysis of the orbofiban in patients with unstable coronary syndromes-thrombolysis in myocardial infarction 16 (OPUS-TIMI 16) trial
    Atar, Shaul
    Cannon, Christopher P.
    Murphy, Sabina A.
    Rosanio, Salvatore
    Uretsky, Barry F.
    Birnbaum, Yochai
    AMERICAN HEART JOURNAL, 2006, 151 (05) : 976.e1 - 976.e6
  • [8] Treatment and outcomes of eastern Europeans with coronary syndromes in OPUS-TIMI 16
    Gurjeva, OS
    Bukhman, G
    Murphy, S
    Cannon, CP
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2005, 100 (01) : 101 - 107
  • [9] Increased platelet reactivity in patients given Orbofiban after an acute coronary syndrome:: An OPUS-TIMI 16 substudy
    Holmes, MB
    Sobel, BE
    Cannon, CP
    Schneider, DJ
    AMERICAN JOURNAL OF CARDIOLOGY, 2000, 85 (04): : 491 - 493
  • [10] Prognostic Evaluation of Catalytic Iron in Patients with Acute Coronary Syndromes: Observations from OPUS-TIMI 16
    Steen, Dylan L.
    Cannon, Christopher P.
    Lele, Suhas
    Rajapurkar, Mohan
    Mukhopadhyay, Banibrata
    Scirica, Benjamin M.
    Morrow, David A.
    CIRCULATION, 2012, 126 (21)
12345